Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study

Apr-09

AUTHORS : Prof Rosalind Raine, UCL Institute of Epidemiology and Health Care, 1-19 Torrington Place, London WC1E 7HB – Email: r.raine@ucl.ac.uk – Profile: https://iris.ucl.ac.uk/iris/browse/profile?upi=RABEN42

JOURNAL : BMJ

REFERENCE: 338:b1279

DOI : 10.1136/bmj.b1279

Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study

More publications

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality

Machine learning prediction algorithms for 2- , 5- and 10-year risk of Alzheimer’s, Parkinson’s and dementia at age 65: a study using medical records from France and the UK General Practitioners